RAIN THERAPEUTICS INC.
8000 Jarvis Avenue, Suite 204
Newark, CA 94560
June 1, 2022
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Rain Therapeutics Inc.
Registration Statement on Form S-3 (File No. 333-265297)
To Whom it May Concern:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the Act), Rain Therapeutics Inc. (the Company) hereby requests that the effective date of the above-referenced registration statement (the Registration Statement) be accelerated to June 6, 2022, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Branden C. Berns at (415) 393-4631.
|Rain Therapeutics Inc.|
|Senior Vice President of Finance and Administration|
Ryan A. Murr, Gibson, Dunn & Crutcher LLP
Branden C. Berns, Gibson, Dunn & Crutcher LLP